Cargando…
Application of a Novel (68)Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients
BACKGROUND: Breast cancer is a heterogeneous disease, and the human epidermal growth factor receptor 2 (HER2) expression may vary considerably between primary and metastatic lesions, or even within a single lesion. Repeated biopsies cannot always be performed. In this feasibility trial, we assessed...
Autores principales: | Miao, Haitao, Sun, Yuyun, Jin, Yizi, Hu, Xichun, Song, Shaoli, Zhang, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195516/ https://www.ncbi.nlm.nih.gov/pubmed/35712499 http://dx.doi.org/10.3389/fonc.2022.894767 |
Ejemplares similares
-
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT
por: Sörensen, Jens, et al.
Publicado: (2016) -
Dynamic PET/CT Imaging of (68)Ga-FAPI-04 in Chinese Subjects
por: Wang, Shuailiang, et al.
Publicado: (2021) -
[(68)Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas
por: Breun, Maria, et al.
Publicado: (2019) -
Preclinical evaluation of (68)Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma
por: Cai, Huawei, et al.
Publicado: (2023) -
HER3 PET Imaging: (68)Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to (89)Zr-Labeled Antibody and Antibody-Fragment-Based Tracers
por: Rinne, Sara S., et al.
Publicado: (2021)